Pharmacoeconomic analyses using discrete event simulation.

Area of Science:

• Health Economics
• Pharmacoeconomics
• Simulation Modeling

Background:

• Traditional pharmacoeconomic evaluations commonly use decision trees and Markov models.
• These methods often lack the flexibility to accurately reflect complex clinical realities.

Purpose of the Study:

• To introduce discrete event simulation (DES) as a superior alternative for pharmacoeconomic modeling.
• To demonstrate the application of DES with a real-world example.

Main Methods:

• Discrete event simulation (DES) was employed to model clinical pathways.
• The approach allows for natural representation of disease progression without fixed cycles or mutually exclusive states.
• Flexibility in handling different perspectives and sensitivity analyses was incorporated.

Main Results:

• DES provides a more natural and flexible way to model clinical reality in economic evaluations.
• The method allows for explicit incorporation of all relevant aspects and transparent presentation.
• Sensitivity analyses, including structural variations, are facilitated.

Conclusions:

• Discrete event simulation (DES) should be strongly considered for pharmacoeconomic evaluations.
• DES is particularly valuable for informing policy decisions and estimating budget impact of pharmaceutical interventions.
• Overcoming data limitations is key to fully realizing the potential of DES in this field.